A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
NCT: NCT07227831 · RECRUITING
Brief Summary
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Frequently Asked Questions
What is A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer?
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer is a clinical trial registered under NCT07227831. Current status: RECRUITING.
What is the status of NCT07227831?
The current status of NCT07227831 (A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer) is: RECRUITING.
When did A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer start?
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer started on 2026-01-16.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.